Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis

被引:52
作者
Al Nofal, A. A. [1 ]
Altayar, O. [2 ]
BenKhadra, K. [3 ]
Agha, O. Q. Qasim [4 ]
Asi, N. [3 ]
Nabhan, M. [5 ]
Prokop, L. J. [3 ]
Tebben, P. [1 ]
Murad, M. H. [3 ,6 ]
机构
[1] Mayo Clin, Div Pediat Endocrinol, Rochester, MN 55905 USA
[2] Alleghany Gen Hosp, Pittsburgh, PA USA
[3] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA
[4] St Josephs Hosp, Phoenix, AZ USA
[5] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA
[6] Mayo Clin, Div Prevent Occupat & Aerosp Med, Rochester, MN 55905 USA
关键词
Bone turnover markers; Paget; Scintigraphy; Total alkaline phosphatase; BIOCHEMICAL MARKERS; BISPHOSPHONATE THERAPY; FAMILIAL AGGREGATION; OSTEOPROTEGERIN; SCINTIGRAPHY; MANAGEMENT; RESPONSES; EFFICACY; MONITOR; FORMS;
D O I
10.1007/s00198-015-3095-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this systematic review and meta-analysis is to study the utility of the commonly used bone turnover markers in evaluating disease activity in patients with Paget's disease of bone before and after treatment with bisphosphonates. We found good correlation between the bone turnover marker concentrations and disease activity assessed by bone scintigraphy. Introduction Paget's disease of bone is a common skeletal disorder of the elderly. Bone turnover marker concentrations are used for diagnosis and follow-up. We aimed to compare the available bone turnover markers and determine their utility in assessing disease activity when compared to quantitative bone scintigraphy. Methods We conducted a systematic review and meta-analysis searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. We evaluated total alkaline phosphatase (total ALP), bone-specific alkaline phosphatase (bone ALP), procollagen type 1 amino-terminal propeptide (P1NP), serum, and urine C-terminal telopeptide (uCTx and sCTx, respectively), and urine N-terminal telopeptide (uNTx). The main outcome of interest was the correlation of disease activity with concentrations of bone turnover markers in Paget's disease patients before and after treatment with bisphosphonates. Correlation coefficients were pooled across studies using the random effects model. Results We included 17 observational studies and one trial reporting on 953 patients. Prior to treatment, all studied bone turnover markers had moderate to strong correlation with scintigraphic indices (correlation coefficients ranging from 0.58 to 0.80) with no statistically significant difference between the bone turnover markers overall (p=0.08). P1NP, uNTx, and bone ALP tend to have higher correlation with scintigraphy. After starting treatment with bisphosphonate, there was moderate to strong correlation with disease activity with all markers except bone ALP (correlation coefficients ranging from 0.43 to 0.70). Conclusion The findings of this meta-analysis suggest the Paget's disease activity is best monitored by following P1NP levels. However, total ALP, bone ALP, and uNTx are good alternatives as markers of disease activity in untreated patients. Total ALP and uNTx can be useful in following patients with Paget's disease after treatment if P1NP is not available. Clinicians, however, should take availability, cost, and the presence of liver disease into consideration when deciding which bone turnover marker is most appropriate when evaluating patients with Paget's disease.
引用
收藏
页码:1875 / 1891
页数:17
相关论文
共 39 条
[1]   Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone [J].
Alexandersen, P ;
Peris, P ;
Guañabens, N ;
Byrjalsen, I ;
Alvarez, L ;
Solberg, H ;
Cloos, PAC .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (04) :588-595
[2]   Prevalence of pelvic Paget's disease of bone in the United States [J].
Altman, RD ;
Bloch, DA ;
Hochberg, MC ;
Murphy, WA .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (03) :461-465
[3]   Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease [J].
Alvarez, L ;
Guañabens, N ;
Peris, P ;
Vidal, S ;
Ros, I ;
Monegal, A ;
Bedini, JL ;
Deulofeu, R ;
Pons, F ;
Muñoz-Gomez, J ;
Ballesta, AM .
BONE, 2001, 29 (05) :447-452
[4]   Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity [J].
Alvarez, L ;
Peris, P ;
Pons, F ;
Guanabens, N ;
Herranz, R ;
Monegal, A ;
Bedini, JL ;
Deulofeu, R ;
deOsaba, MJM ;
MunozGomez, J ;
Ballesta, AM .
ARTHRITIS AND RHEUMATISM, 1997, 40 (03) :461-468
[5]   Components of biological variation of biochemical markers of bone turnover in Paget's bone disease [J].
Alvarez, L ;
Ricós, C ;
Peris, P ;
Guañabens, N ;
Monegal, A ;
Pons, F ;
Ballesta, AM .
BONE, 2000, 26 (06) :571-576
[6]   Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone.: Proposed intervals for monitoring treatment [J].
Alvarez, L ;
Peris, P ;
Guañabens, N ;
Vidal, S ;
Quintó, L ;
Monegal, A ;
Pons, F ;
Ballesta, AM ;
Muñoz-Gómez, J .
RHEUMATOLOGY, 2004, 43 (07) :869-874
[7]  
[Anonymous], 2014, NEWCASTLE OTTAWA SCA
[8]  
[Anonymous], WALTERS MED STAT TXB
[9]   Monostotic Paget's disease of the femur: A diagnostic challenge and an overlooked risk [J].
Bachiller-Corral, J. ;
Diaz-Miguel, C. ;
Morales-Piga, A. .
BONE, 2013, 57 (02) :517-521
[10]   Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone [J].
Bonnin, MR ;
Moragues, C ;
Nolla, JM ;
Liron, FJ ;
Roig-Escofet, D ;
Navarro, MA .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1998, 36 (01) :53-55